Thalassemia

Introduction

Thalassemia is an inherited blood disorder that affects how the body makes haemoglobin — the protein in red blood cells that carries oxygen. When haemoglobin is made in lower amounts or in an abnormal form, red blood cells do not work as well, and the result is a long-standing anaemia (low red blood cell count). Thalassemia is one of the most common inherited disorders in the world, and it is especially common in parts of South Asia, the Mediterranean, the Middle East, and Southeast Asia.

This article is written for people who have been diagnosed with thalassemia and for parents of children who have been diagnosed. It explains what the condition is, the different types, how it is diagnosed and monitored, and the treatments used today — from simple monitoring in mild forms to regular blood transfusions, iron chelation, and bone marrow (stem cell) transplant for severe forms. It also covers daily life, complications to watch for, and what to expect over the years.

Thalassemia is a lifelong condition for most people who have a clinically significant form, but the outlook has improved dramatically over recent decades. With well-organised care, many children with even the severe forms now grow into adults with active lives and growing families of their own.

What Is Thalassemia?

Red blood cells contain haemoglobin, which is made of two kinds of protein chains: alpha (α) globin chains and beta (β) globin chains. A healthy adult haemoglobin molecule has two alpha chains and two beta chains joined together. The instructions for making these chains come from genes inherited from both parents.

In thalassemia, one or more of these genes is changed (mutated) so that the body makes too little of one of the globin chains. The imbalance between alpha and beta chains damages red blood cells, leading to them being smaller than normal (microcytic), paler than normal (hypochromic), and shorter-lived. The bone marrow tries to compensate by producing more red blood cells, but they remain ineffective — a pattern doctors call ineffective erythropoiesis.

The result is anaemia, which in severe cases starts in the first months or years of life and, without treatment, prevents normal growth and causes life-threatening complications. In milder forms, the anaemia may be mild and discovered only on a routine blood test.

Thalassemia is genetic and inherited. It is not caused by diet, infection, or anything either parent did. A person is either born with it or not. Carriers of a single thalassemia gene (called thalassemia minor or trait) usually have no symptoms and may not even know they carry it until a blood test or genetic screening reveals it.

Types of Thalassemia

Thalassemia is grouped first by which globin chain is affected (alpha or beta), and then by how severely red blood cell production is reduced. The clinically important categories are described below.

Beta Thalassemia

Beta thalassemia is caused by changes in the gene that codes for beta globin chains. Each person inherits two copies of this gene — one from each parent. The severity depends on how many copies are affected and how much function remains.

• Beta thalassemia minor (trait): Only one gene copy is affected. Most people have no symptoms or only very mild anaemia. They are carriers and can pass the gene on to children.
• Beta thalassemia intermedia: Both gene copies are affected but some beta chain production is preserved. Anaemia is moderate. Some people need occasional transfusions; others manage without regular transfusions for long periods. This is sometimes called non-transfusion dependent thalassemia.
• Beta thalassemia major (Cooley's anaemia): Both gene copies are severely affected and very little or no beta globin is made. Severe anaemia appears in the first 6 to 24 months of life. Lifelong regular blood transfusions are needed. This is the form often referred to as transfusion-dependent thalassemia.

Alpha Thalassemia

• Silent carrier (one gene affected): No symptoms; normal blood counts in most cases.
• Alpha thalassemia trait (two genes affected): Mild anaemia, often mistaken for iron deficiency.
• Haemoglobin H disease (three genes affected): Moderate to severe anaemia, sometimes needing occasional transfusions, with risk of enlarged spleen and bone changes.
• Alpha thalassemia major (all four genes affected): This is also called haemoglobin Bart's hydrops fetalis. It is usually fatal before or shortly after birth without specialised in-utero treatment.

Haemoglobin E and Combined Forms

Haemoglobin E is a common variant in Southeast Asia and parts of India. When it is inherited together with a beta thalassemia mutation, the result is haemoglobin E/beta thalassemia, which can range from mild to as severe as beta thalassemia major. Many people in the eastern parts of India and in Bangladesh have this form.

Causes and Inheritance

Thalassemia is passed from parents to children. The pattern of inheritance is called autosomal recessive for most clinically significant forms. This means a child develops the severe disease only if they inherit an affected gene from both parents.

• A 25% chance the child will have beta thalassemia major
• A 50% chance the child will be a carrier (trait), like the parents
• A 25% chance the child will have neither the trait nor the disease

These odds apply to each pregnancy independently — they do not change based on what has already happened in earlier pregnancies. Genetic counselling helps families understand their specific situation, including more complex inheritance patterns when one parent has trait and the other has a haemoglobin variant like haemoglobin E or sickle cell trait.

Thalassemia is common in regions where malaria has historically been present. Researchers believe that carrying a single thalassemia gene gives some protection against severe malaria, which is why the trait is so widespread in these populations.

Signs and Symptoms

For readers who already have a diagnosis, this section is most useful as a reminder of what well-controlled disease looks like and what changes might signal a complication or the need to revisit treatment.

In thalassemia major, untreated symptoms in infancy and early childhood include pale skin, poor feeding, failure to grow at the expected rate, irritability, and an enlarged spleen and liver. Over time, untreated severe thalassemia causes characteristic changes to facial bones and skull, frequent infections, and heart failure. With regular transfusions started early, most of these features are prevented.

In thalassemia intermedia and haemoglobin H disease, common features include chronic mild to moderate anaemia, fatigue with exertion, jaundice (yellowing of the skin and eyes from rapid red cell turnover), enlarged spleen, gallstones, and leg ulcers in some adults.

In thalassemia minor (trait), most people have no symptoms. Mild anaemia may show up on a routine test and is sometimes mistaken for iron deficiency.

Signs that should prompt contact with your haematology team include: increasing tiredness between transfusions, new shortness of breath, palpitations or chest pain, sudden severe abdominal pain (which may indicate gallstones or splenic problems), new bone pain, fever, or jaundice that is worse than usual.

Diagnosis

For most patients reading this, diagnosis has already been made. This section explains what the tests are and may show, so you can understand your own reports and follow-up testing.

Blood Tests

A complete blood count (CBC) typically shows anaemia with red cells that are smaller (low MCV) and paler (low MCH) than normal. A peripheral blood smear shows characteristic red cell shapes and target cells.

Haemoglobin Analysis

Haemoglobin electrophoresis or high-performance liquid chromatography (HPLC) measures the different types of haemoglobin in the blood. This is the main test that identifies beta thalassemia, haemoglobin E, sickle cell, and other variants. In beta thalassemia, the level of haemoglobin A2 is typically raised.

Genetic Testing

DNA testing identifies the exact gene mutation. This is especially useful for alpha thalassemia (which is not always seen on electrophoresis), for confirming carrier status in family members, and for planning future pregnancies.

Iron Studies

Because thalassemia can look like iron deficiency on a CBC, doctors usually also check serum ferritin, iron, and transferrin saturation. This is also important because, after transfusions begin, iron overload becomes a major issue and ferritin is one of the markers followed lifelong.

Prenatal and Newborn Diagnosis

In couples where both partners are known carriers, prenatal diagnosis is possible. This is performed through chorionic villus sampling (typically at 11–13 weeks of pregnancy) or amniocentesis (typically from around 15 weeks). These tests check whether the fetus has inherited two affected genes. Genetic counselling before and after testing is an important part of the process. In some regions, newborn screening programmes also detect thalassemia early.

Treatment and Management

The right treatment depends on the type and severity of thalassemia. The main approaches are described below. Major paediatric haematology bodies, including the Thalassaemia International Federation (TIF), publish detailed guidelines that haematology teams worldwide follow.

Monitoring Only

People with thalassemia minor (trait) and most silent alpha carriers do not need ongoing treatment. They benefit from knowing their status for family planning and from avoiding being mistakenly treated with long-term iron supplements for what looks like iron deficiency.

Regular Blood Transfusions

For thalassemia major and for intermedia patients whose anaemia or complications become significant, regular red blood cell transfusions are the foundation of care. The aim is to keep haemoglobin levels high enough to support normal growth in children, prevent bone marrow over-activity, and prevent complications.

Most patients on a regular transfusion programme receive blood every two to four weeks. Modern programmes use leucodepleted red cells (red cells with the white cells filtered out) to reduce reactions, and carefully match blood groups beyond the basic ABO and Rh system to reduce the risk of forming antibodies over many years of transfusion.

Iron Chelation Therapy

Each unit of transfused blood adds iron to the body. Over time, transfusion iron overload damages the heart, liver, and endocrine glands (including those that produce growth and reproductive hormones). The body has no natural way to remove this excess iron, so iron chelation — medication that binds iron and helps the body excrete it — is essential.

• Deferasirox: Taken by mouth, usually once a day. It is the most commonly used chelator in many regions today because of its convenience.
• Deferiprone: Taken by mouth several times a day. It is particularly effective at removing iron from the heart and is sometimes combined with deferasirox or deferoxamine.
• Deferoxamine: Given as a slow infusion under the skin (subcutaneous) over several hours, usually five to seven nights a week. It is older but very effective and is used alone or in combination.

The choice of chelator is a clinical decision made together with the haematology team, based on age, iron load in different organs, side effects, kidney and liver function, and how well the person tolerates each option. Iron levels are monitored through blood ferritin, and more accurately through MRI of the liver (LIC measurement) and cardiac T2* MRI, which estimate iron in those organs.

Bone Marrow (Stem Cell) Transplant

Bone marrow transplant, also called haematopoietic stem cell transplantation (HSCT), is currently the only well-established curative treatment for severe thalassemia. Healthy blood-forming stem cells from a matched donor replace the patient's faulty ones, and over time the new cells produce normal haemoglobin.

The best outcomes are seen when:

• The patient is young (transplants in children typically have better outcomes than in adults)
• Iron overload is well controlled
• The donor is a fully matched sibling

Matched unrelated donor transplants and half-matched (haploidentical) family transplants are also performed in experienced centres, with outcomes that continue to improve. The decision to pursue transplant weighs the chance of cure against the risks of the transplant itself, which include infection, rejection, graft-versus-host disease, and longer-term effects of conditioning treatment.

Gene Therapy

Gene therapy for beta thalassemia has moved from research into approved treatment in some countries in recent years. In these approaches, the patient's own stem cells are removed, modified to produce functional haemoglobin, and returned to the body. This avoids the risk of graft-versus-host disease that comes with donor transplants. Access to gene therapy is currently limited to specialised centres and specific patient groups.

Other Medications

Luspatercept is a newer injectable medication that helps red blood cells mature more effectively. It is approved in some regions for adults with transfusion-dependent beta thalassemia and can reduce the number of transfusions needed in some patients.

Hydroxyurea is used in some patients with thalassemia intermedia and certain combined disorders to boost fetal haemoglobin production.

Splenectomy

The spleen sometimes becomes very enlarged and overactive in thalassemia, destroying red cells faster and increasing transfusion needs. Surgical removal of the spleen (splenectomy) is sometimes done when transfusion requirements become very high. Because the spleen plays a role in fighting infections, splenectomy is now performed less often than in earlier decades, and when done is accompanied by vaccinations and sometimes long-term preventive antibiotics.

Lifestyle and Self-Management

Living well with thalassemia involves more than scheduled hospital visits. Day-to-day habits make a real difference to how someone feels and to long-term health.

Diet and Iron

People on regular transfusions usually do not need extra iron and should avoid iron supplements unless specifically prescribed. A balanced diet that includes calcium, vitamin D, folic acid, and zinc supports red blood cell production and bone health. Tea with meals can modestly reduce iron absorption from food and is sometimes suggested. Specific dietary plans are best discussed with the haematology team or a dietitian who knows the condition.

Folic Acid

Folic acid supplements are commonly recommended in thalassemia because the bone marrow is constantly trying to make new red cells and uses up folate faster than usual.

Exercise

Most people with thalassemia — including those on transfusion programmes — can and should be physically active. Activity tolerance varies with haemoglobin levels and organ status. Children should be encouraged to take part in school sports, with intensity adjusted to how they feel rather than restricted by default.

Vaccinations

Routine childhood vaccinations are important. Extra vaccinations — including against hepatitis B, pneumococcus, meningococcus, and influenza — are usually given, especially in patients who have had a splenectomy or are on transfusions.

Avoiding Infections

People who have had splenectomy or who have iron overload are at higher risk from certain infections. Good general hygiene, prompt attention to fevers, and following the team's plan for antibiotics during illness all matter.

Alcohol and Smoking

Alcohol adds to liver stress in people who already carry extra iron in the liver, and smoking accelerates heart and lung damage. Both are best avoided.

Monitoring and Targets

Long-term care of thalassemia is built on regular reviews. The exact schedule depends on the type and severity, but typical elements include:

• Pre-transfusion haemoglobin: Checked at each transfusion to keep the average above a level that protects growth and bone marrow.
• Ferritin: Usually every 1–3 months in transfused patients, to guide chelation dose.
• Liver iron concentration (LIC) by MRI: Typically once a year or as guided by the team.
• Cardiac T2* MRI: Typically once a year from school age onward in transfused patients.
• Endocrine review: Growth, puberty, thyroid, parathyroid, glucose tolerance, and bone density, because iron can affect all of these glands.
• Liver function tests and hepatitis screening: Because of historical transfusion-related hepatitis risk and the effects of iron on the liver.
• Heart assessment: ECG and echocardiogram at intervals advised by the team.
• Antibody screening: Before transfusions to detect new antibodies that may complicate future matching.

Children also have growth, development, and dental reviews. Adults add cardiovascular risk, fertility, and bone health to the list of regular checks.

Complications

Most long-term complications of thalassemia come from one of two sources: the disease itself (chronic anaemia and over-active bone marrow) or the side effects of treatment (iron overload from transfusions). With modern care, many of these are prevented or delayed.

Iron Overload

Bone Disease

Low bone density (osteoporosis) is common, especially in adults. Causes include the underlying disease, endocrine effects of iron, vitamin D deficiency, and some medications. Bone density scans, vitamin D, calcium, and treatment of hormonal deficiencies are all part of long-term management.

Heart Disease

Cardiac iron overload was historically the leading cause of death in beta thalassemia major. Cardiac T2* MRI and improved chelation have dramatically reduced this risk in the past two decades.

Endocrine and Growth Problems

Delayed puberty, short stature, hypothyroidism, hypoparathyroidism, and diabetes can all occur. Regular endocrine review allows early treatment.

Liver Disease

Iron, viral hepatitis (from transfusions before modern screening), and fatty liver can all contribute. Annual liver assessment and treatment of hepatitis C where present are important.

Splenic Problems and Gallstones

An enlarged, overactive spleen can worsen anaemia. Rapid red cell breakdown produces extra bilirubin, which can lead to gallstones.

Thrombosis

People with thalassemia intermedia, especially after splenectomy, have a higher risk of blood clots. This is part of why splenectomy is now performed more cautiously.

Transfusion-Related Issues

These include allergic and febrile reactions, formation of antibodies against red cells that makes future matching harder, and historically transmission of infections (which is now very rare with modern screening).

Living with Thalassemia

For most readers, this is the largest part of the story. The condition is lifelong, but life with it has changed enormously in a generation.

School and Work

Most children with thalassemia attend regular school and do well academically. Time off for transfusions and clinic visits needs to be planned with the school. Letting key teachers know — without making the child feel different — helps with practical arrangements such as catching up on work or managing fatigue around transfusion days.

In adulthood, most people work in regular jobs. Some careers that involve very heavy physical work or unpredictable travel schedules may be harder to combine with a strict transfusion schedule, but many flexible options exist.

Relationships and Family Planning

Many adults with thalassemia have partners and children. Fertility may be affected by iron-related effects on the pituitary and ovaries or testes, and supported fertility treatments are sometimes needed. Genetic counselling before pregnancy is very important. If the partner is also a carrier, the family can discuss the options for prenatal diagnosis or pre-implantation testing with a specialist.

Pregnancy

Pregnancy is possible for many women with thalassemia, including those with thalassemia major, but it needs careful planning with a haematologist and a high-risk obstetrician. Chelation regimens are usually changed around conception and during pregnancy. Heart and liver iron should be well controlled before pregnancy is attempted.

Mental Health

Living with a chronic condition, especially one that involves regular hospital visits from childhood, can affect mental health. Anxiety around transfusions, fear of complications, body image concerns, and the strain of long treatment routines are all common. Support from psychologists familiar with chronic illness, peer support groups, and patient associations all help.

Travel

Travel is possible with planning. Transfusion schedules can sometimes be adjusted, and links can be arranged between centres in different cities or countries for transfusions away from home. A current medical summary and a list of medications are useful to carry.

Thalassemia in Children

Because most severe thalassemia is diagnosed in early childhood, paediatric care has its own particular focus. The main goals during childhood are:

• Normal growth and development: Adequate transfusion support keeps haemoglobin levels high enough for normal growth velocity. Growth, weight, and pubertal development are tracked at every clinic visit.
• Early and effective iron chelation: Chelation is typically started after a child has received a certain number of transfusions or once ferritin rises above a threshold. Starting chelation later than needed is one of the avoidable causes of long-term complications.
• Vaccinations and infection prevention: Following the standard schedule plus extra vaccines as advised by the team.
• Education and emotional adjustment: Helping the child understand their condition in age-appropriate ways. Older children can take part in decisions about their care.
• Family support: Parents and siblings of a child with thalassemia carry a real load. Family counselling, peer parent groups, and clear communication with the medical team all help.
• Planning around transplant: If a matched sibling donor exists in the family, the team will usually discuss the option of bone marrow transplant relatively early, since outcomes are best in younger children with well-controlled iron load.

School-age children with thalassemia generally do as well academically as their classmates. Activity should be encouraged rather than restricted, with sensible adjustment around transfusion days when they may feel more tired.

Prevention of Complications and of New Cases in the Family

While the inherited condition itself cannot be undone in someone who already has it, two kinds of prevention matter:

Preventing Complications in the Patient

Almost all the long-term complications of thalassemia are at least partly preventable through:

• Consistent transfusion attendance to keep haemoglobin levels in target range
• Taking iron chelation as prescribed, every day
• Attending all monitoring appointments — MRIs, endocrine reviews, heart and liver checks
• Treating endocrine problems early, before they affect growth or fertility
• Vaccination and infection awareness
• Avoiding alcohol and tobacco

Preventing New Affected Pregnancies in the Family

Many regions with high thalassemia frequency have screening programmes for carriers. When carrier status is known before a couple has children, options include:

• Genetic counselling to understand the risks for each pregnancy
• Prenatal diagnosis (chorionic villus sampling or amniocentesis) during pregnancy
• Pre-implantation genetic testing during in-vitro fertilisation (IVF), in which embryos are tested before being placed in the uterus

These options are personal decisions and benefit from non-directive counselling. Siblings, cousins, and extended family of a person with thalassemia are often offered screening for trait, since this information can shape future family planning.

When to Seek Urgent Care

For someone living with thalassemia, certain situations should prompt urgent contact with the haematology team or a visit to emergency services:

• Fever, especially after splenectomy or in someone with a central line
• Sudden severe abdominal pain or rapid increase in abdominal size
• New chest pain, shortness of breath at rest, or palpitations
• Swelling of the legs or sudden weight gain (possible heart-related fluid build-up)
• Severe headache, weakness on one side, or sudden vision changes
• Sudden severe back pain or limb swelling (possible blood clot)
• Reactions during or shortly after a transfusion — rash, breathing difficulty, fever, dark urine
• Persistent vomiting or inability to take chelation tablets

Frequently Asked Questions

Is thalassemia the same as anaemia?

Anaemia means a low red blood cell count or low haemoglobin, and it has many causes. Thalassemia is one specific inherited cause of anaemia. The anaemia in thalassemia is not corrected by iron tablets, because the problem is not lack of iron but a fault in haemoglobin production.

Can thalassemia be cured?

For severe forms, bone marrow (stem cell) transplant offers a potential cure. Gene therapy is also now an option in some countries for selected patients. For most people, treatment focuses on managing the condition well over the long term rather than curing it. Mild forms (trait) do not need a cure because they cause no disease.

Is thalassemia contagious?

No. Thalassemia is inherited, not infectious. It cannot be passed from one person to another except through inheritance from parent to child.

If I have thalassemia trait, will my children definitely have the disease?

Not necessarily. A child develops the severe disease only if they inherit an affected gene from both parents. If only one parent carries the trait, children may inherit the trait themselves but will not develop the severe form. Couples who are both carriers benefit from genetic counselling before or during pregnancy.

Why am I told not to take iron supplements?

The anaemia in thalassemia is not due to low iron. Taking iron tablets can add to the iron already present in the body and, especially in people on transfusions, contributes to harmful iron overload. Iron should only be taken if a specific iron deficiency is confirmed alongside thalassemia, and only under medical advice.

Can adults be newly diagnosed with thalassemia?

Yes. Mild forms such as thalassemia trait and some cases of thalassemia intermedia or haemoglobin H disease are often first identified in adulthood, sometimes during routine blood tests, during evaluation for unexplained mild anaemia, or during pregnancy screening.

Will pregnancy be safe if I have thalassemia major?

Pregnancy is possible for many women with thalassemia major and is increasingly common. It requires careful planning with a haematologist and a high-risk obstetrician, optimisation of iron levels before conception, and adjustment of medications. Outcomes are generally good when these steps are followed.

Can people with thalassemia live a normal lifespan?

The outlook has improved very significantly. With well-organised transfusion and chelation programmes and modern monitoring, many people with even the severe forms of thalassemia now reach adulthood, work, raise families, and live decades longer than was possible a generation ago. Life expectancy continues to improve with each advance in treatment.

How long does a transfusion take, and how often is it needed?

A typical transfusion of two units of red blood cells takes around three to four hours. Most patients with transfusion-dependent thalassemia receive transfusions every two to four weeks. Schedules are individualised by the haematology team.

Is bone marrow transplant an option for everyone?

Transplant is currently offered to selected patients, with the best outcomes seen in younger patients who have a fully matched sibling donor and well-controlled iron overload. Whether transplant is the right choice for a particular person is a clinical decision that weighs the chance of cure against the risks of the procedure.

Conclusion

Thalassemia is a lifelong inherited condition, but it is one in which good organised care has changed the outlook dramatically over the past few decades. For someone with thalassemia trait, awareness and family planning are usually all that is needed. For someone with intermedia or major forms, a partnership with an experienced haematology team — built around regular transfusions when needed, careful iron chelation, monitoring of the heart, liver, and endocrine system, and attention to general health — allows most people to grow, work, build families, and live full lives.

For some patients, bone marrow transplant or gene therapy can now offer a cure. For others, the best path is steady long-term management. Whichever path applies, the most important factors are consistent care, honest communication with the medical team, and the support of family and community around the person living with the condition.